New chalcone derivatives having pyrazole and sulfonamide pharmacophores as carbonic anhydrase inhibitors
Background: Sulfonamide, pyrazole and chalcone pharmacophores are an important compounds in medicinal chemistry. They have wide range of biological activities including carbonic anhydrase (CA) inhibitory activities. Introduction: Carbonic anhydrase I and II inhibitors are used for the treatment of some disease such as retinal and cerebral edema (CAI), edema, epilepsy, and glaucoma (CA II). The available drugs in market have some limitations or side effect problems. So, there is a need to develop new drug candidate compound/s to overcome the problems at issue. In this study, a series of compounds MS4-MS10, (E)-4-(4-(3-aryl)-3-oxoprop-1-en-1-yl)-3-phenyl-1H-pyrazol-1-yl) benzenesulfonamides, were designed to discover new carbonic anhydrase inhibitors using hibryd approach. Methods: The compounds MS4-MS10 were synthesized as shown in Scheme 1 and their chemical structures were confirmed by 1H NMR, 13C NMR and HRMS spectra. Carbonic anhydrase (CAs, E.C.4.2.1.1) inhibitory effects of MS4-MS10 were tested on the hCA I and II isoenzymes by previously reported procedures. Results and Discussons: Carbonic anhydrase inhibitors results of the MS4-MS10 were presented in Table 1 as IC50 values (nM). They were inhibition range of 27.8-87.3 towards hCA I and 24.4-54.8 towards hCA II while reference drug AAZ IC50 values were 384.2 (hCA I) and 36.9 (hCA II). MS7 and MS9 had 13.8 (hCA I) and 1.5 (hCA II) times more potent CA inhibition than reference compound AAZ, respectively. Conclusion: MS7 (Ar: 2,4,5-trimethoxy phenyl) towards hCA I and MS9 (Ar: 3,4-dimethoxy phenyl) towards hCA II were the lead compounds of our series with the lowest IC50 value and can be considered for further studies.